Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Lycia Therapeutics
Biotech
Lycia leaps onto Nasdaq with $318M IPO as Windward eyes debut
Lycia Therapeutics went public with an upsized $317.5 million IPO on Friday, while Windward Bio is hoping to catch the same tailwinds.
James Waldron
Oct 26, 2026 10:00am
Lycia aims for $228M IPO to advance food allergy rival to Xolair
Oct 20, 2026 10:52am
TRex eyes $111M IPO, as Retension and Lycia also look to Nasdaq
Oct 6, 2026 3:47am
Neumora overhauls C-suite after phase 3 flop—Chutes & Ladders
Feb 14, 2025 8:30am
Lilly-backed Lycia Therapeutics nabs $70M round
Sep 9, 2021 7:00am
Lilly doubles down on protein degradation with $35M Lycia deal
Aug 25, 2021 11:17am
